NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

Bobbie J. Rimel, Danielle Enserro, David P. Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor Backes, Elizabeth Swisher, Matthew Powell, Helen MacKay

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Keyphrases